Author

Mina T Kelleni

Minia University, College of Medicine, Pharmacology Department - Cited by 852

Biography

Dr. Mina T Kelleni is One of the top 0.7 % COVID-19 experts among over 416,090 authors worldwide (Expertscape). Egyptian general practitioner, senior consultant and assistant professor of pharmacology whose professional medical practice evolved together with his passion for innovative pharmacotherapy since 2006. Author of dozens of academic publications with ubiquitous medical research aiming mostly at drug discovery for several chronic and acute diseases ranging from diabetes mellitus, cancer to COVID-19 as well as raising awareness about drug pharmacovigilance in the developing countries
Title
Cited by
Year
Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment
MT KelleniSN Comprehensive Clinical Medicine 3 (4), 919-923, 2021202
44
2021
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects
MT KelleniExpert Review of Anti-infective Therapy 20 (1), 17-21, 2022202
31
2022
Resveratrol protects against cisplatin-induced ovarian and uterine toxicity in female rats by attenuating oxidative stress, inflammation and apoptosis
MA Ibrahim, IA Albahlol, FA Wani, AAE Tammam, MT Kelleni, MU Sayeed, ...Chemico-Biological Interactions 338, 109402, 2021202
31
2021
Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy
MT KelleniBiomedicine & Pharmacotherapy 139, 111626, 2021202
23
2021
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience
MT KelleniCanadian Journal of Medicine 3, 121-143, 212
20
2021
COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators
MT KelleniImmunologic Research, 2021202
15
2021
SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality
MT KelleniJournal of Infection 82 (2), e35, 2021202
12
2021
NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?
MT KelleniInflammopharmacology 30 (1), 343-348, 2022202
10
2022
SARS CoV-2 vaccination autoimmunity, antibody dependent Covid-19 enhancement and other potential risks: beneath the tip of the iceberg
MT KelleniInt J Pulm Respir Sci 5 (2), 1-10, 2021202
7
2021
Evolution of SARS CoV-2 omicron subvariants BF. 7 and XBB. 1.5: time to follow Africa and abort all COVID restrictions
MT KelleniJournal of Infection 8 (4), 405, 2023202
6
2023
ACE2 polymorphisms interplay with the apelinergic peptide system: potential tools for COVID-19 diagnosis and treatment
M KelleniOSFPREPRINTS, 2021202
6
2021
Non-steroidal Anti-inflammatory Drugs/nitazoxanide/azithromycin Potential Beneficial COVID-19 Effects: Preventing the Cytokine Storm via Mitigation of the Interleukin-6 …
Non-steroidal Anti-inflammatory Drugs/nitazoxanide/azithromycin Potential Beneficial COVID-19 Effects: Preventing the Cytokine Storm via Mitigation of the Interleukin- …MT KelleniOSFPREPRINTS, 2021202
6
2021
SARS CoV-2 adenovirus and RNA based vaccines potential autoimmune complications: could we lower the chances?
M KelleniAuthorea Preprints, 2021202
6
2021
SARS CoV-2 Might Exploit Cells of the Innate Immune System to Induce the Novel Acute Immune Dysrhythmic Syndrome (n-AIDS) and Para COVID-19 Syndrome.
M KelleniOSF Preprints, 2021202
5
2021
The potential crucial role of COX-1 inhibition and/or Aspirin triggered lipoxins and resolvins in amelioration of COVID-19 mortality
M KelleniOSF Preprints, 2021202
5
2021
BCG vaccination potential for COVID-19: an analytical approach
MT KelleniHuman Vaccines & Immunotherapeutics 17 (8), 28-250, 2021202
4
2021
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Children and Pregnant COVID-19 Patients: An Egyptian Prospective Observational Study.
M KelleniOSF Preprints, 2021202
3
2021
Paxlovid and Molnupiravir Approved to Manage COVID-19: A Countdown for SARS CoV-2 Variant Apocalypse.
M KelleniOSF Preprints, 2021202
3
2021
SARS CoV-2 Vaccines, Remdesivir and Favipiravir Might Have Led to SARS CoV-2 B. 1.617 Variants: India First but We Can Intervene
SARS CoV- Vaccines, Remdesivir and Favipiravir Might Have Led to SARS CoV- B. 1.617 Variants: India First but We Can InterveneM KelleniAuthorea Preprints, 010
2
2021
NSAIDs, SARS CoV-2 ORF Proteins, Caspases, and CARD14: Solving the Mystery of COVID-19 and Beyond
NSAIDs, SARS CoV- ORF Proteins, Caspases, and CARD14: Solving the Mystery of COVID-19 and BeyondM KelleniOSF Preprints, 010
2
2021

Referred From: https://scholar.google.com/citations?user=TZcfzCQAAAAJ&hl=en

Cited by
Citations 852
h-index 14
i10-index 16
Open Access Journals